Vials of the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic in Valparaiso, Chile, on January 3, 2022.
Rodrigo Garrido | Reuters
Pfizer issued a sales guidance of $67 billion to $71 billion for 2023 on Tuesday, down from record 2022 results.
The drug company booked $100.3 billion for full-year 2022, an all-time high, driven by more than $50 billion in sales of Covid vaccines and antivirals.
Pfizer expects sales for 2023 to fall by as much as 33% compared to 2022 as the pandemic eases and demand for its Covid portfolio falls. The company expects $13.5 billion in 2023 Covid vaccine sales and $8 billion in revenue for Paxlovid.
Pfizer is forecasting earnings of between $3.25 and $3.45 per share for 2023, down 50% from a record $6.58 in 2022. The company reported net income of $31.4 billion in 2022, a 43% increase from 2021.
Pfizer’s stock fell 3% in premarket trading.
The drugmaker’s fourth-quarter results broadly met analysts’ expectations. The company reported net income of nearly $5 billion for the quarter, up 47% from the same period in 2021. It generated revenue of $24.3 billion for the quarter.
Here’s how the company performed versus Wall Street’s expectations for the fourth quarter, based on average analyst estimates compiled by Refinitiv:
Read CNBC’s latest global health coverage:
Picture this: a bustling apartment complex filled with tenants who reliably pay rent every month.…
Metformin has been used for decades. Not as a wellness trend. Not as a supplement…
Ashton Kutcher does not bother anyone with this beauty treatment. At least the company doesn't.…
The logo of pharmaceutical company Novo Nordisk is seen outside its offices in Bagsvaerd on…
Donald Trump is by far the pettiest president in US history. He never forgets an…
Defense stocks in Europe and Asia rose sharply on Monday as investors gauged that the…
This website uses cookies.